Arquer Diagnostics
@ArquerDx
SYNLAB UK is now able to offer #ADXBLADDER as part of their diagnostic portfolio. #Urologists interested in this service can contact adxbladder@synlab.co.uk today. https://t.co/devm9K7XDy 
Arquer Diagnostics
@ArquerDx
At Arquer, we are honoured to have worked with so many of the #hospitals that are featured in Newsweek's #WorldsBestHospitals2020. We are extremely proud of everything we have accomplished alongside these institutions and look forward to working with more of them in the future. https://t.co/PMiSUVyzBs 
Arquer Diagnostics
@ArquerDx
Monitoring #patients who have successfully undergone treatment for #bladdercancer is of crucial importance. #ADXBLADDER can add a new accuracy to these routine follow-up procedures, making the detection of bladder cancer recurrence easier than ever before. https://t.co/2dbOGWaJXm 
Arquer Diagnostics
@ArquerDx
With 99% NPV and a very high sensitivity in high-grade tumors, #ADXBLADDER can outperform #cytology and eliminate the need for #bladdercancer patients to undergo multiple #cystoscopies during follow-up procedures. Read more about this on our latest blog: https://t.co/K2A96yZagU. https://t.co/YXTxHNSkEQ 
Arquer Diagnostics
@ArquerDx
#ADXPROSTATE, our test for #prostatecancer, is currently undergoing clinical trials. It's with this product that we hope to simplify and speed up #diagnosis of this form of cancer, improving the outcomes of those affected by this condition across the globe. https://t.co/ZLy80xKnnX 
Arquer Diagnostics Announces Exclusive Agreement with SYNLAB to Accelerate the Introduction in the UK of Game-Changing non-invasive Diagnostic test for Patients with Suspected Bladder Cancer
Sunderland, United Kingdom, 13th July 2020 – Arquer Diagnostics, a UK-based company committed to manufacturing and marketing innovative, non-invasive tests for diagnosing and monitoring cancer, today announced that it has entered into an exclusive agreement with SYNLAB UK & Ireland, a leading medical diagnostic services provider.